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Abstract: Objective: To summarize major clinical trials which evaluate the efficacy and safety data of approved disease 
modifying agents for the treatment of various types of multiple sclerosis.  
Data Sources: A MEDLINE (1966 to August 2008) search of clinical trials using the terms multiple sclerosis, interferon, 
glatiramer, mitoxantrone and natalizumab was performed. A manual bibliographic search was also conducted. English-
language articles identified from the searches were evaluated. New agents under investigation in phase 3 clinical trials 
were identified using www.clinicaltrials.gov. 
Study Selection & Data Extraction: Relevant information was identified and selected based on clinical relevance and evi-
dence-based strength. Prescribing information leaflets were used to provide usual dosage, contraindications, precautions, 
monitoring parameters and other relevant drug-specific information. 
Data Synthesis: Interferon beta products are more efficacious for the treatment of relapsing-remitting multiple sclerosis. 
Interferon beta 1-b also delayed the time to diagnosis of definite multiple sclerosis and reduced brain lesion burden in pa-
tients with clinical isolated syndrome. Glatiramer and natalizumab have both established efficacy in relapsing forms of 
multiple sclerosis; whereas mitoxantrone is more commonly used in patients with advanced disease. There are limited 
data the comparative efficacy among different disease modifying agents. New agents currently under investigation have 
showed promising results and may offer more treatment options in the future. 
Conclusions: MS is a complex and devastating disease with challenging treatment considerations and approaches. Inter-
feron beta products continue to be the mainstay of therapy in many patients, however, other treatments are proving to be 
at least as effective in the management of various types of MS. Newer compounds are being developed and studied with 
much anticipation and promise for the clinical management of the disease. 
Keywords:  Multiple sclerosis, disease modifying therapy, immune modulators, interferon beta, glatiramer, mitoxantrone,   
natalizumab. 
INTRODUCTION 
  Multiple sclerosis (MS) is a debilitating condition that 
affects approximately 400,000 Americans and 2.5 million 
people worldwide [1-3]. It is usually diagnosed between age 
20 and 50, and affects women twice more often than men 
[1]. Risk factors include geographic location, ethnicity and 
genetics [2]. Scandinavian descent and persons who live 
further away from the equator are more likely to be inflicted 
[4, 5]. Although the familial recurrence rate of MS is low  
(~ 5%), a positive family history can increase the risk by 30 
to 50 times [2, 6]. About 15% of patients with MS have at  
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least one additional relative suffering from the disease [2, 6]. 
Concordance data shows a higher prevalence of MS among 
monozygotic (25%) than among dizygotic twins (3-5%) [5, 
7]. Disability due to MS can accumulate and reduce life span 
by 6 to 7 years and patients survive for about 35-40 years 
from the time of diagnosis [2, 8]. This article provides an 
overview of MS, as well as a review of the agents commonly 
used to manage its symptoms and progression.  
PATHOPHYSIOLOGY AND ETIOLOGY 
  The exact causes of MS are unclear. Autoimmune and 
microbial etiologies have been proposed to explain the 
pathophysiology of MS. In the autoimmune etiology theory, 
a patient’s own immune system attacks against myelin or 
oligodendrocyte antigens [1, 2, 9]. This leads to the stripping 
of myelin sheath which is a protein-lipoid substance sur-
rounding the neuronal axons. Myelin sheath insulates, pro-
tects, and helps to conduct nerve impulses. Demyelination, 
together with inflammatory responses, leads to the formation 
of characteristic lesions in the central nervous system (CNS). 16     The Open Neurology Journal, 2010, Volume 4  Hilas et al. 
This destructive process leads to axonal damage even early 
in the disease and may result in neurologic symptoms, which 
typically reflect the affected area of the CNS [1, 2, 9]. 
  In the microbial etiology theory, bacteria or viruses are 
responsible for the pathogenesis of MS. Suspected organisms 
include varicella zoster, rubella, Epstein-Barr, human herpes 
virus 6, mycoplasma, rabies virus, canine distemper virus, 
retrovirus, mumps, measles, Chlamydia pneumoniae, and 
others. Nevertheless, no one particular pathogen has been 
fully established as a causal agent for MS symptoms [1, 2, 9-
12].  
  Environmental factors may also contribute to the patho-
genesis [13]. MS is more prevalent in countries with moder-
ate or cool climate, areas with greater distances from the 
equator in both the northern and southern hemispheres [1]. 
Interestingly, the environmental influence is more important 
between the ages of 10 and 15 years [13, 14]. 
CLINICAL MANIFESTATIONS 
  MS has a variable clinical presentation with its clinical 
course or disease progression related to the type of MS [2, 
15]. The disease consists of four distinct types or stages: (1) 
relapsing-remitting MS (RRMS); (2) secondary progressive 
MS (SPMS); (3) primary progressive MS (PPMS); and pro-
gressive-relapsing MS (PRMS) [2, 15, 16, 20]. 
  RRMS is the most common type, affecting approxi-
mately 80 to 85% of patients beginning in their second or 
third decade of life and clinically manifesting in the third or 
fourth decade [2, 15, 17]. Women are twice as likely to pre-
sent with this type of MS [2]. Signs and symptoms usually 
present over a course of days, typically stabilizing and spon-
taneously resolving. Disability and CNS dysfunction may 
present and progress after relapses, and during times of re-
mission [2, 15]. Initial symptoms include sensory, visual, 
balance and gait disturbances, limb weakness, neurogenic 
bladder and bowel problems. Temporal fatigue and increases 
in body temperature have also been reported. In addition, 
cognitive impairment, depression, emotional lability, 
dysarthria, dysphagia, vertigo, progressive quadriparesis and 
sensory loss, ataxic tremors, pain, sexual dysfunction, spas-
ticity, and other apparent CNS problems may arise [2].  
  An estimated 50% of RRMS patients over a period of 10 
years [18] and about 90% over 25 years will experience a 
stage transition to SPMS [16]. SPMS is characterized by a 
gradual and worsening disability with or without the pres-
ence of superimposed relapses [17, 19]. Exacerbations may 
or may not be seen during the secondary progressive stage 
[20].  
  PPMS affects approximately 10-20% of patients and car-
ries the worst prognosis [2, 17]. The incidence has been re-
ported to be similar among men and women [2]. It is charac-
terized by a gradual and progressive course in which patients 
experience continuous worsening in disease from onset with 
no exacerbations or remission periods [2, 20]. Initial presen-
tation includes a slow progressive myelopathy of the legs. 
Quadraparesis, cognitive decline, visual loss, brain-stem 
syndromes, and dysfunction of bowel, bladder, and repro-
ductive systems may also occur [2]. 
  A fourth and unusual type, referred to as progressive-
relapsing MS (PRMS), has also been introduced as a pro-
gressive disease from onset with clear, acute and superim-
posed relapses with or without recovery [20]. However, one 
study found that there was no differentiation between pri-
mary progressive and progressive-relapsing based on clinical 
characteristics and progression of disability [21]. 
  All types of MS can cause significant disability [15]. 
Although it is difficult to predict the progressive course and 
development of disability [17], poor prognostic factors have 
been described: male gender, older age at onset, motor symp-
toms or cerebellar signs at onset, short interval and incom-
plete recovery between the initial and subsequent attack, 
high relapse rate early on in disease, early disability, moder-
ate disability within 5 years and high lesion load revealed on 
early magnetic resonance imaging (MRI) of the brain [16, 
18, 22, 23].  
DIAGNOSIS 
  Currently, no specific diagnostic test is available for MS. 
Therefore, appropriate diagnosis depends on thorough his-
tory and examination and objective evidence of CNS lesions 
scattered in space and time [24, 25]. An MRI is utilized to 
support the clinical diagnosis, confirm dissemination in 
space, and rule out other potential causes such as metabolic, 
vascular, psychiatric, genetic, autoimmune, neuropathic, 
neoplastic and other disorders [2]. It is the most sensitive and 
specific technique for detecting MS lesions and quantifying 
their progression over time [26]. Typical findings include 
multifocal lesions of various ages primarily involving the 
periventricular white matter, brain stem, cerebellum, and 
spinal cord white matter. In addition, the presence of gado-
linium-enhanced lesions indicates inflammatory demyelina-
tion [2]. 
  Cerebrospinal fluid (CSF) analysis and visual evoked 
potentials (VEP) are also used to further assist in the diagno-
sis. CSF analysis provides information on inflammatory and 
immunologic disturbances, while VEP provide physiologic 
evidence of optic nerve dysfunction. Somatosensory evoked 
potentials (SEP) detect spinal cord dysfunction, and can pro-
vide diagnostic support when used along with spinal MRI [2, 
24].  
  In 2000, the International Panel on the Diagnosis of MS 
developed the McDonald Criteria [24]. Core features of 
these diagnostic criteria include: emphasis on objective 
clinical findings; dependence on evidence of dissemination 
of lesions in time and space; use of supportive and confirma-
tory paraclinical examination; focus on specificity rather 
than sensitivity; and elimination of better explanations for a 
diagnosis [24, 27]. In the 2005, its revisions called for a par-
ticular focus on MRI criteria for dissemination of lesions in 
time, incorporation of spinal cord lesions into the imaging 
requirements, and establishing a diagnosis of PPMS by con-
centrating on clinical and imaging evidence and placing less 
emphasis on CSF findings [27]. 
APPROVED DISEASE MODIFYING AGENTS 
Interferon  
 Interferon   (IFN) is produced by fibroblasts and has 
antiviral, antiproliferative, and immunomodulatory effects 
[28]. Currently, there are two types of IFN available: IFN-
1a and IFN-1b (Table 1). IFN-1a is identical to natural 
IFN, while IFN-1b has a serine substitution for cysteine at Disease Modifying Agents for Multiple Sclerosis  The Open Neurology Journal, 2010, Volume 4    17 
position 17 [29]. Also of note, IFN-1a is glycosylated, 
while IFN-1b is not [29]. 
Interferon -1a 
 IFN-1a is available as two different formulations: a 
once weekly intramuscular (IM) injection (Avonex
®) and a 
three times weekly (TIW) subcutaneous (SC) injection (Re-
bif
®). Intramuscular IFN-1a was approved by the FDA in 
May 1996 following two clinical trials that demonstrated 
efficacy. In one double-blind, placebo-controlled study, pa-
tients with RRMS were randomized to receive either IFN-
1a 30mcg IM once weekly (n = 158) or placebo (n = 143) for 
up to 104 weeks [30]. The primary outcome was the time to 
Table 1.  FDA Approved Disease-Modifying Agents for the Management of Multiple Sclerosis 
 
Drug Mechanism  of  Action Approved  
Indication 
Usual Dosage  Notes 
Interferon beta-1a 
(Avonex
®) 
Anti-proliferation, immunomodula-
tion 
RRMS  30 mcg SC once weekly    
Interferon beta- 1a 
(Rebif
®) 
Anti-proliferation, immunomodula-
tion 
RRMS  20% of target dose initially, titrate 
to 22 mcg or 44 mcg IM TIW over 
4 weeks 
Administer on the same 
days each week, at least 48 
hours apart 
Interferon beta-1b 
(Betaseron
®) 
Anti-proliferation, immunomodula-
tion 
RRMS, CIS with 
MRI features 
consistent with 
MS 
0.0625 mg SC QOD initially; 
increase to 0.25 mg QOD over 6 
weeks 
CBC and LFT at baseline 
and 1,3,6 months thereafter; 
TFT every 6 months in 
selected patients 
Glatiramer (Copax-
one
®) 
Competitive binding with MBP, 
cytokine modulation & inhibition of 
free radical 
RRMS  20 mg SC daily  Routine laboratory monitor-
ing is not required 
Mitoxantrone 
(Novantrone
®) 
Intercalates into DNA; interferes with 
RNA; inhibits topoisomerase II; anti-
proliferation; immunomodulation; 
TNF- and IL-2 inhibition 
SPMS, PRMS, or 
worsening RRMS 
12mg/m
2 IV infusion over 5-15 
minutes every 3 months 
Bone marrow suppression 
(neuropenia) may occur. 
CBC should be monitored 
prior to initial dose, before 
each subsequent dose, and 
after discontinuation of 
therapy 
Assessment of cardiac func-
tion recommended prior to 
initiation, during treatment 
and yearly after discontinua-
tion (history, physical ex-
amination, electrocardio-
gram and quantitative 
evaluation of left ventricular 
ejection fraction via echo-
cardiogram, multi-gated  
radionuclide angiography 
(MUGA), MRI, etc.) 
LFT should be 
monitored prior to initial 
dose and before each subse-
quent dose  
Secondary acute 
myelogenous leukemia 
(AML) has been reported. 
Elevated risk of 0.25% has 
been observed 
Natalizumab  
(Tysabri
®) 
Inhibits the adhesion of molecules 
onto the surface of immune cells; 
potentially inhibits the migration of 
immune cells  
Monotherapy for 
relapsing forms of 
MS 
300mg IV infusion over approxi-
mately one hour every 4 weeks 
(data on the efficacy and safety is 
limited to two years) 
CBC, WBC, LFT (including 
bilirubin) should be moni-
tored regularly 
Antibody testing upon initia-
tion and at 3 months (if 
persistent antibodies are 
suspected) 
Hypersensitivity/ anaphy-
laxis may occur within 2 
hours of infusion 
Gadolinium-enhanced brain 
MRI and CSF analysis for 
JC viral DNA are recom-
mended for suspected PML 
MBP = myelin binding proteins; TNF = tumor necrosis factor; IL = interleukin; CIS = clinical isolated syndrome; RRMS = relapsing-remitting multiple scleroris; MRI = magnetic 
resonance imaging; SPMS = secondary progressive multiple sclerosis; PRMS = progressive relapsing multiple sclerosis; SC = subcutaneously; QOD = every other day; IV = intrave-
nously; CBC = complete blood count; LFT = liver function tests; TFT = thyroid function tests; CSF = cerebrospinal fluid; PML = progressive multifocal leukoencephalopathy. 18     The Open Neurology Journal, 2010, Volume 4  Hilas et al. 
onset of sustained disease disability, as defined by a decrease 
from baseline expanded disability status scale (EDSS) scores 
of at least 1 point for at least 6 months. Other outcomes in-
cluded the number of exacerbations and brain lesions. Of the 
patients who completed 104 weeks of the study, 85 received 
IFN and 87 received placebo. The primary outcome, time to 
sustained progression of disease disability, was significantly 
prolonged in the interferon group as compared to the placebo 
group (p = 0.02). The number of exacerbations were signifi-
cantly lower in the interferon group (0.82 vs 0.67 per year 
per patient; p = 0.04) when looking at all patients. The dif-
ference was more pronounced in the patients who completed 
104 weeks of treatment, where the number of exacerbations 
per year per patient was 0.90 in the placebo group and 0.61 
in the IFN group (p=0.002). At the end of one year, 29.9% in 
the IFN group and 42.3% in the placebo group (p=0.05) had 
positive MRI scans. At the end of year two, the percentages 
of positive MRI scans were similar: 28.9% vs 42.7%, respec-
tively (p=0.02). Overall, IFN was well-tolerated. The ad-
verse events that occurred more often in the IFN group in-
cluded flu-like symptoms, muscle aches, fever, and chills.  
  The second study on IM IFN-1a was a randomized, 
double-blind, placebo-controlled, multicenter trial in patients 
who had recently experienced their first demyelinating event 
involving the optic nerve, brainstem, cerebellum, or spinal 
cord, and also had to have subclinical lesions on MRI [31]. 
Patients first received a regimen of methylprednisolone 1g 
IV for 3 days, then prednisone 1mg/kg orally for 11 days, 
then a 4 day period of steroid taper. Patients were then ran-
domized to receive either IFN-1a 30mcg IM once weekly 
(n=193) or placebo (n=190) for 3 years. Cumulative prob-
ability of developing clinically confirmed MS during the 3 
years was significantly decreased in the IFN group (rate 
ratio 0.56; 95%CI 0.38-0.81; p=0.002). On MRI, the number 
of new or enlarging lesions was significantly lower in the 
IFN group at months 6 (p=0.001), 12 (p<0.001), and 18 
(p<0.001). The volume of lesions seen on MRI also signifi-
cantly decreased in the IFN group at 6 (p<0.001), 12 
(p=0.004), and 18 months (p<0.001). Influenza-like symp-
toms and depression occurred statistically more often in the 
IFN group.  
 Subcutaneous  IFN-1a was approved by the FDA in May 
2002 following the completion of two clinical trials: Preven-
tion of Relapses and Disability by IFN-1a Subcutaneously 
in Multiple Sclerosis (PRISMS-2) and Evidence of Inter-
feron Dose-Response: European North American Compara-
tive Efficacy (EVIDENCE). The PRISMS-2 was a multicen-
ter, double-blind, placebo-controlled trial enrolling 560 pa-
tients with RRMS [32]. Patients were randomly assigned to 
receive SC IFN-1a 22mcg, 44mcg, or placebo TIW for 2 
years. Ninety percent of patients completed this study. The 
mean number of relapses decreased significantly in the IFN 
groups: 2.56 placebo, 1.82 IFN 22mcg (p<0.005 vs placebo), 
and 1.73 IFN 44mcg (p<0.005 vs placebo). Time to pro-
gression was longer in both IFN groups compared to pla-
cebo (p<0.05). The percentage of relapse-free patients over 2 
years was 27% in the 22mcg group (p<0.05 vs placebo), 32% 
in the 44mcg group (p<0.005 vs placebo), and 16% in the 
placebo group. Statistically significant responses were seen 
in the IFN groups for decreased positive MRI scans and 
other endpoints. Overall, IFN-1a was well-tolerated. Injec-
tion-site reactions, lymphopenia, increased liver function test 
(LFT), and granulocytopenia were reported more often 
among the IFN groups. 
  Results of a 2 year follow up study (PRISMS-4) were 
later published [33]. During years 3 and 4 of the study, pa-
tients originally receiving placebo were randomized in a 
double-blind fashion to receive IFN-1a 22mcg TIW or 
44mcg TIW; data for this group was pooled as the “cross-
over” group. Patients originally receiving either dose of 
IFN continued that dose through years 3 and 4. Results 
showed that patients who received IFN-1a for the entire 4 
years had fewer relapses per year (22 mcg, 0.80 per year; 
44mcg, 0.72 per year) than patients who received 2 years of 
placebo and 2 years of IFN (1.02 per year).  
  The EVIDENCE study was an active-controlled, multi-
center trial that compared three times weekly SC IFN-1a 
with once weekly IM IFN-1a (Avonex
®) for 2 years in pa-
tients with RRMS [34]. Patients were randomly assigned to 
receive either IFN-1a SC 44mcg TIW (n=33) or IFN-1a 
IM 30mcg once weekly (n=388). At the end of 2 years, 75% 
in the SC group and 63% in the IM group were relapse-free 
(OR 1.9; 95%CI 1.3-2.6; p=0.0005). Patients in the SC group 
had fewer lesions on MRI than the IM group (p<0.0001). 
The time to first relapse was prolonged for the patients in the 
SC group as compared to the IM group (HR 0.70; 95%CI 
0.55-0.88; p=0.003). Lower relapse rates were seen in the SC 
group (0.29 vs. 0.40 relapses/patient; p=0.022). Adverse 
events were more common in the SC group than in the IM 
group, with injection-site reactions, systemic influenza-like 
symptoms, LFT abnormalities, and white blood cell abnor-
malities occurring more often.  
  An extension of the EVIDENCE study was later pub-
lished in which patients were followed for an average of 32 
additional weeks [35]. In this phase of the study, patients 
originally assigned to receive IM IFN-1a were switched to 
the SC form, while those originally receiving the SC form 
continued in that group. The primary outcome was the 
change in relapse rate from pre-transition to post-transition. 
A total of 223 patients who were originally receiving the IM 
dose were switched to SC (IM to SC group), and 272 contin-
ued their originally SC dose (continuing SC group). Post-
transition, the relapse rate per year decreased from 0.64 to 
0.32 in the IM to SC group (p<0.001), and decreased from 
0.46 to 0.34 in the continuing SC group (p=0.03). Patients in 
the continuing SC group had fewer T2-weighted lesions on 
MRI after the switch (p=0.02), while the SC continuing 
group had no change in number of lesions. Patients in the IM 
to SC group had more adverse events, and more patients in 
this group stopped treatment due to an adverse event. Injec-
tion-site reactions, influenza-like symptoms, LFT abnormali-
ties, and white blood cell abnormalities occurred more often 
post-transition in the IM to SC group.  
  Both forms of IFN-1a are indicated for the treatment of 
relapsing forms of MS [36, 37]. The frequency of admini-
stration may affect the expression of biologic effect markers, 
indicating differences in therapeutic efficacy. In a study con-
ducted in 1999, subjects were administered IFN-1a 22mcg 
once weekly, 22mcg TIW, or 66mcg once weekly. Levels of 
proinflammatory cytokines including tumor necrosis factor-
, interferon-, interleukin-1, interleukin-6, and tumor ne-
crosis factor- decreased with the increase in dosing fre-
quency (22mcg once weekly vs. TIW), not by the increase in Disease Modifying Agents for Multiple Sclerosis  The Open Neurology Journal, 2010, Volume 4    19 
absolute dose (22mcg once weekly vs 66mcg once weekly) 
[38]. 
Interferon -1b 
 IFN-1b (Betaseron
®) is the first disease modifying agent 
approved by the FDA in 1993. It is indicated for RRMS ini-
tially, and then also for clinical isolated syndrome (CIS) with 
MRI features consistent with MS [39].  
  In a multi-center, double-blind, placebo-controlled trial, 
IFN-1b reduced exacerbation rates, severity of exacerba-
tions, and accumulation of MRI abnormalities. There was 
also an insignificant reduction of disability [40, 41]. In this 
trial, 372 patients with RRMS were randomized to receive 
placebo and IFN-1b (1.6 or 8 MIU SC every other day) for 
2 years. IFN-1b demonstrated dose-dependent efficacy in 
annual exacerbation rates (1.27, 1.17 and 0.84, respectively). 
More patients receiving IFN-1b remained exacerbation-free 
(36 vs. 18 placebo; p = 0.007). IFN-1b also significantly 
delayed the time to first exacerbation by up to 142 days. 
Overall, IFN-1b had a persistent beneficial effect on exac-
erbation rate for up to 3 years and MRI burden of disease for 
up to 5 years [42]. Reported side effects include lym-
phopenia, liver enzyme elevation inflammation at injection 
site, fever, and myalgia.  
  The efficacy and safety of IFN-1b in patients with CIS 
has been demonstrated in a multi-center, randomized, dou-
ble-blind, placebo-controlled, 2-year trial involving 468 pa-
tients [43]. Enrolled patients experienced a first clinical de-
myelinating event and at least two clinically silent brain MRI 
lesions. Treatment with IFN-1b significantly delayed the 
time to diagnosis of clinically definite MS by 50% and 
McDonald MS by 46%. It also significantly reduced secon-
dary MRI endpoints, including newly active lesions and 
change in T2 lesion volume. Most common reported side 
effects were injection site reactions, flu-like syndrome, and 
headache. Incidence of depression was comparable in both 
groups (10% vs. 11%). 
  Treatment with IFN-1b provided conflicting results in 
patients with SPMS in two multi-center, randomized, dou-
ble-blind, placebo-controlled trials [44, 45]. In EU-SPMS 
trial, IFN-1b significantly delayed the progression of dis-
ability in European patients with SPMS. The study was ter-
minated one month early due to a compelling evidence of 
efficacy. Fewer patients receiving IFN-1b had confirmed 
disease progression (39% vs. 50%, p = 0.0048). Overall, 
treatment with IFN-1b delayed progression for 9-12 months 
(OR 0.65; 95% CI 0.52-0.83). This beneficial effect was 
seen in patients with superimposed relapses and those with 
only progressive deterioration without relapses. IFN-1b 
also provided beneficial effects on relapse rate, relapse se-
verity, MRI variables and time to becoming wheelchair-
bound in this 3-year study [44]. The most common reported 
side effects were flu syndrome, injection site inflammation, 
injection site reaction, fever, and hypertonia. 
  Unfortunately, this efficacy was not reproducible in a 
similar study involving North Americans (NA-SPMS trial) 
[45] that enrolled 939 subjects with SPMS, but was halted 
approximately 3 months early due to a lack of efficacy. Al-
though IFN-1b improved clinical relapses and MRI vari-
ables, it did not delay the time to confirmed progression of 
disability [45]. 
  There are no clear explanations for the contrasting results 
seen in EU-SPMS [44] and NA-SPMS [45] trials, but differ-
ences in patient baseline characteristics may have played an 
important role [46]. Evidences suggested that patients with 
ongoing inflammatory activity, as evidenced by pronounced 
disability progression and ongoing relapses, may benefit 
more from IFN-1b therapy [47]. It has been speculated that 
subjects in the EU-SPMS trial were more subject to treat-
ment benefit compared to those in the NA-SPMS trial. The 
pooled analysis of both trials showed that treatment with 
IFN-1b provided a 20% risk reduction in EDSS progression 
confirmed at 6 months (p = 0.008). Higher risk reduction 
(30% to 40%) was seen in patients with at least one relapse 
or change in EDSS by >1 in the 2 years prior to study entry 
[47].  
  Even though all IFNs induce neutralizing antibodies, 
IFN-1a seems to be less immunogenic that IFN-1b, possi-
bly due to its glycosylation [29, 48, 49]. In one study con-
ducted in 2006, IM IFN-1a induced neutralizing antibodies 
at a lower rate (5%; p<0.0001) than SC IFN-1a (29%) and 
interferon -1b (31%) [49]. The frequency of binding anti-
bodies followed the same pattern. However, in the subgroup 
of patients testing positive for neutralizing antibodies, more 
patients receiving IFN-1a had high titers compared to pa-
tients receiving IFN-1b (p=0.04). This may be the reason 
that many patients who develop neutralizing antibodies to 
IFN-1b eventually return to negative neutralizing antibody 
titers, since higher antibody levels indicate that the antibod-
ies will persist [50]. The IFNs also differ in the extent of 
liver injury they can cause. A retrospective chart review pub-
lished in 2004 evaluated aminotransferase levels in 835 pa-
tients receiving the three IFNs [51]. The authors concluded 
that SC IFN-1b and IFN-1a led to similar elevations of 
aminotransferase levels, and these were higher than the lev-
els caused by IM IFN-1a. 
Glatiramer 
  Glatiramer, or copolymer-1 (Copaxone
®) is the acetate 
salt of a random mixture of synthetic polypeptides composed 
of L-glutamic acid, L-lysine, L-tyrosine, and L-alanine (Ta-
ble 1) [52]. It reduces relapses and MRI findings in patients 
with RRMS [53-56]. In a double-blind, randomized, pla-
cebo-controlled 2-year pilot trial that involved 48 patients, 
glatiramer reduced relapse rate by about 4-fold (0.6 vs 2.7 
placebo) [54]. Significantly more patients receiving 
glatiramer remained exacerbation-free at the end of the study 
(56% vs. 26%). Similar results were noted in a double-blind, 
placebo-controlled, 2-year, phase 3 trial in 251 patients with 
RRMS [55]. Glatiramer significantly reduced annualized 
relapse rate by 29% (0.59 vs. 0.84; p = 0.007) with a more 
profound benefit in subjects with lower EDSS scores of 0 to 
2. Nevertheless, glatiramer did not provide benefit in sus-
tained disability progression, defined as a 1.0 point or greater 
increase in EDSS maintained for 90 days. Drug-related side 
effects were injection-site reactions (90% vs. 59% placebo) 
and transient self-limiting systematic reactions, characterized 
by flushing, chest pain, palpitation, anxiety and dyspnea 
(15% vs. 3%). In a randomized, placebo-controlled extension 
trial [56], glatiramer provided similar benefit in relapse rate 
reduction (32%), and demonstrated benefit on disability pro-
gression, defined as worsening by 1.5 or greater on the 
EDSS (p = 0.001). Local injection site reactions occurred 20     The Open Neurology Journal, 2010, Volume 4  Hilas et al. 
more commonly in the glatiramer group (66% vs. 37% pla-
cebo). Immediate systemic reactions were noted with 
glatiramer use (1%% vs. 3.2% placebo) [56]. 
  Follow-up analyses compared the neurologic status of 
subjects who remained on glatiramer therapy with those who 
withdrew from therapy in a 10-year period [57]. Results 
showed that more patients who remained on glatiramer ther-
apy had stable or improved EDSS scores (68% vs. 28%). 
Still, glatiramer was associated with injection site reactiosn 
(erythema, pain, mass, edema) and immedidate post-
injection reaction (vasodilation, chest pain, palpitation, 
tachycardia or dyspnea) [57]. Unlike interferons, glatiramer 
is not associated with flu-like reactions or depression and 
does not seem to worsen headaches [58, 59]. Glatiramer is a 
Category B drug but use during pregnancy and breast-
feeding is not recommended [52]. 
  Glatiramer has also reduced MRI-measured disease ac-
tivity and burden among RRMS patients in a randomized, 
placebo-controlled, 9-month study that involved 239 patients 
[60]. The glatiramer group had a significant reduction in the 
total number of enhancing lesion In another study, glatiramer 
significantly reduced the likelihood of new T2 lesions after 7 
and 8 months, and provided a favorable effect on tissue dis-
ruption in MS lesions [61]. In addition, a small study showed 
that glatiramer may be an option for continuing disease 
modification in patients with RRMS who received prior 
treatment with mitoxantrone [62], or IFN treatments [63, 
64].  
  A randomized, placebo-controlled, 3-year (PROMISE) 
trial was planned to evaluate the effect of glatiramer in de-
laying time to confirmed disease progression in 943 patients 
with PPMS. Unfortunately, it was halted early due to signifi-
cant dropout of patients (26.4%) and marked slower annual 
progression rate in the placebo group (16.1% compared to an 
expected rate of 50%) [65].  
Mitoxantrone 
  Mitoxantrone was approved by the FDA in October 
2000, and is indicated for the reduction of neurologic disabil-
ity and/or frequency of clinical relapses in patients with 
SPMS, PRMS, or worsening RRMS (Table 1). The approval 
of mitoxantrone was based on two phase III clinical trials. 
The first study was a multicenter, double-blind, placebo-
controlled, trial conducted in patients with SPMS or PRMS 
[66, 67] A total of 194 patients were enrolled and 188 pa-
tients were included in an intent-to-treat analysis at 24 
months. Patients were randomized to receive either mitoxan-
trone 5mg/m
2, mitoxantrone 12mg/m
2 or placebo IV every 3 
months for 24 months.  
  In comparing mitoxantrone 5mg/m
2, mitoxantrone 
12mg/m
2 or placebo, the mean EDSS changes was 0.23, 0.13 
and 0.23, mean ambulation index changes was 0.41, 0.30 and 
0.77, mean number of relapses treated with corticosteroids 
was 0.73, 0.40 and 1.20, median months to first relapse re-
quiring corticosteroids was 6.9, 20.4, 6.7, and mean stan-
dardization neurological status change was 0.38, 1.07, 0.77, 
respectively (all p values significant). 
  In regards to the subset of patients undergoing MRI as-
sessment, the number of patients with new gadolinium-
enhancing lesions was 11%, 0% and 18% in the mitoxan-
trone 5mg/m
2, mitoxantrone 12mg/m
2 and placebo groups, 
respectively (p=0.022). The mean number of patients in 
which a change in the number of T2-weighted lesions were 
34, 28 and 32, respectively. 
  Mitoxantrone was most frequently reported to cause mild 
or moderate nausea, urinary tract infections, menstrual dis-
orders including amenorrhea, and mild alopecia, compared to 
the placebo group. Approximately 9.7% (6/60) of patients in 
the mitoxantrone 12mg/m
2 group discontinued treatment due 
to the occurrences of leukopenia, depression, decreased left 
ventricular function, bone pain, emesis, renal failure and 
prevention of recurrent urinary tract infections, compared to 
the 3.1% (2/64) in the placebo group due to hepatitis and 
myocardial infarction. No deaths or serious drug-related 
events occurred during the study. 
  The second study
 was a controlled trial conducted to as-
sess the efficacy and safety of combination mitoxantrone and 
methylprednisolone in patients with SPMS or worsening 
RRMS who experienced residual neurological deficit be-
tween relapses [66]. At screening, patients were initiated on 
a two-month protocol consisting of monthly doses of meth-
ylprednisolone 1g IV, as well as monthly MRI scans. Pa-
tients who had developed at least one new gadolinium-
enhancing lesion during this time were randomized and in-
cluded in the study, A total of 42 patients were then random-
ized to receive either methylprednisolone 1g IV monthly or 
approximately 12mg/m
2 of mitoxantrone IV plus methyl-
prednisolone 1g IV for a total of 6 months. All completed the 
study except five patients in the methylprednisolone group, 
due to lack of efficacy,  
  More patients in the mitoxantrone plus methylpredniso-
lone group had no new gadolinium-enhancing lesions at 6 
months (90% vs 31%; p=0.001). In addition, the mean EDSS 
change among the groups was -1.1 and -0.1 (p=0.013), mean 
annual relapse rate per patient was 0.7 and 3.0 (p=0.003) and 
percentage of patients without relapses was 67% and 33% 
(p=0.031) for combination and methylprenidolone alone 
groups, respectively. 
  The most frequently reported adverse effects reported in 
the mitoxantrone plus methylprednisolone group, versus the 
methylprednisolone alone group included amenorrhea, 
alopecia, nausea, and asthenia. Leukopenia, neutropenia, and 
mild to moderate infections were also reported at a higher 
rate in the combination therapy group. 
  In a multicenter study, the efficacy of mitoxantrone over 
24 months was compared to placebo in the proportion of 
patients with confirmed progression of MS [68]. Fifty-one 
patients with clinically definite or laboratory-supported 
RRMS were were randomized to receive either mitoxantrone 
8mg/m
2 IV over 30 minutes monthly for 1 year or placebo.  
  A statistically significant difference in the proportion of 
patients with confirmed progression of MS as measured by 
at least one point on the EDSS was seen at 24 months and 
the total study period (baseline to 24 months) between the 
treatment and placebo groups (0% vs. 25%, p=0.01; 7% vs 
37%, p=0.02). No significant differences were noted on the 
mean change of EDSS scores between the two groups at 12 
or 24 months. A significant decrease in the mean number of 
annual exacerbations was reported when comparing mitax-
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at 24 months (0.37 vs. 1.1, p=0.005). The number of exacer-
bation-free patients were also found to be statistically sig-
nificant between the groups at 12 months (70% vs. 25%, 
p=0.003) and at 24 months (78% vs. 42%, p =0.01). All 51 
patients completed the MRI study except 9 patients due to 
perceptions of treatment inefficacy, lack of compliance or 
non-medical reasons. No significant differences in the devel-
opment of new or enlarged lesions were noted at 12 or 24 
months between the two study groups, however, a greater 
reduction in the number of new lesions was noted in the mi-
toxantrone group. 
  The most frequently reported side effects in the mitoxan-
trone group were mild or moderate nausea, urinary tract and 
upper respiratory infections, headache, and diarrhea. Five 
women experienced transient amenorrhea. 
Natalizumab  
 Natalizumab  (Tysabri
®) is the first recombinant human-
ized monoclonal antibody that was approved by the FDA in 
November 2004 for use in RRMS (Table 1). It was voluntar-
ily withdrawn from the market by the manufacturer in Feb-
ruary 2005 due to 2 reports of progressive multifocal leu-
koencephalopathy (PML), including one fatal case. In addi-
tion, a third patient developed PML in another open label 
trial involving the use of natalizumab in Crohn’s disease 
[69]. In July 2006, after a thorough review of all patients 
exposed to this agent and additional clinical trials evaluating 
its safety and efficacy, the FDA allowed natalizumab to re-
turn to the market with a block-box warning of PML and 
under strict safety restrictions and provisions. This agent is 
only available to certified practitioners, infusion centers and 
pharmacies registered through a special restricted distribu-
tion program known as the TOUCH™ (Tysabri
® Outreach: 
Unified Commitment to Health) Prescription Program [69, 
70]. Most recently, two European patients were reported to 
develop PML prompting the FDA to report an alert in 
August 2008. Natalizumab is currently indicated for mono-
therapy in the treatment of relapsing forms of MS. It is used 
to delay the accumulation of physical disability and to re-
duce the frequency of clinical exacerbations.  
  Two phase III clinical trials were pivotal in the approval 
of natalizumab for use in patients with MS. In the first study, 
942 patients with a diagnosis of relapsing MS were included 
[71, 72]. This was a multicenter, double-blind, placebo-
controlled, trial which enrolled patients who had not re-
ceived INF or glatiramer for the previous 6 months. Eligi-
ble patients were randomly assigned (2:1) to receive either 
natalizumab 300mg or placebo by IV infusion every 4 weeks 
for up to 116 weeks.  
  Results revealed better clinical and MRI endpoints for 
patients in the natalizumab group at 2 years (p<0.001). Sev-
enteen percent of the natalizumab group versus 29% of the 
placebo group had a sustained increase in disability. There 
was a relative risk reduction of 42% at 2 years in the natali-
zumab group (0.22 vs. 0.67 annual relapse rate). More pa-
tients in the natalizumab group remained relapse free at two 
years (67% vs. 41%).  
  The most frequently reported serious adverse effects 
among the natalizumab and placebo groups were infections, 
acute hypersensitivity reactions, depression, and cholelithia-
sis. Other adverse events which were significantly more 
common in the natalizumab group included headache, fa-
tigue, arthralgia, pain in extremity, abdominal discomfort, 
diarrhea and rash. 
  The second multicenter, double-blind, placebo-controlled 
parallel-group trial [71, 73] enrolled patients with RRMS (n 
= 1196), however, only 1171 of these patients were included 
in data analysis. All patients received treatment with INF-
1a for at least 12 months and experienced at least one relapse 
during the 12-month period prior to study initiation. Patients 
were randomly assigned to receive either 300mg of natali-
zumab or placebo IV every 4 weeks, in addition to 30mcg of 
INF-1a administered IM once weekly for up to 116 weeks. 
Combination therapy was reported to have a 24% reduction 
in the relative risk of sustained disability (p=0.02), with a 
lower cumulative probability of sustained disability progres-
sion at two years (23% vs. 29%; p=0.02). Combination ther-
apy was also associated with a lower annualized rate of re-
lapse as compared to INF-1a (0.38 vs. 0.82 at one year, 
p<0.001; 0.34 vs. 0.75 at two years; p<0.001). The risk of 
relapse was reported to be 50% lower with combination 
therapy (p<0.001); 54% in the combination group and 32% 
in the INF-1a group alone (p<0.001) were relapse-free at 
two years. In addition, natalizumab produced a 92% reduc-
tion in gadolinium-enhancing lesions (2.4 vs. 0.2; p<0.001), 
an 83% reduction in new or enlarging T2-hyperintense le-
sions (11.0 vs. 1.9; p<0.001) and a 76% reduction in new T1-
hypointense lesions (4.6 vs. 1.1; p<0.001) over the two year 
period.  
  Commonly reported adverse events of the combination 
group included anxiety, pharyngitis, sinus congestion and 
peripheral edema. The incidence of infection was similar in 
both the combination and INF-1a alone group. The most 
common serious adverse event among both study groups was 
MS relapse. Appendicitis was also more common in natali-
zumab patients. The trial was stopped approximately one 
month prior to the anticipated date due to 2 cases of natali-
zumab associated PML.   
  In another multicenter, double-blind, placebo-controlled 
trial, a total of 213 patients with clinically definite or labora-
tory-supported definite RRMS or SPMS were enrolled and 
included in the intent-to-treat analysis [74]. Patients were 
randomized to receive either natalizumab 3mg/kg, natalizu-
mab 6mg/kg, or placebo administered by IV infusion every 
28 days for a total of 6 months. Physical and neurological 
examinations were performed at monthly, at which time ad-
verse events were also recorded.  
  Over 6 months, reductions in the number of new lesions 
in the natalizumab 3mg/kg, 6mg/kg and placebo groups were 
0.7, 1.1 and 9.6 per patient, respectively)p<0.001;). Relapses 
were seen in 13, 13 and 27 patients respectively, (p=0.02). 
The placebo group reported a slight worsening in well-being 
with a mean decrease of 1.38mm (on a 100-mm visual-
analogue scale). An improvement in well-being was reported 
in both the 3mg/kg natalizumab and 6mg/kg natalizumab 
groups (a mean increase of 9.49mm and 6.21mm, respec-
tively). The 3mg/kg natalizumab group had a mean of 0.7 
new gadolinium-enhancing lesions per patient (p<0.001), 1.1 
in the 6mg/kg natalizumab group, and 9.6 in the placebo 
group (p<0.001). No significant difference in values was 
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  Subgroup analysis demonstrated the efficacy of natali-
zumab over placebo in reducing new enhancing lesions in 
both RRMS and SPMS patients. Natalizumab also caused 
marked reductions in the numbers of persistent enhancing 
lesions and new active lesions, the total volume of enhancing 
lesions, and the percentage of scans showing activity. In ad-
dition, fewer natalizumab-treated patients requires corticos-
teroid treatment for relapses. No significant changes in the 
EDSS scores were observed in any group during the six-
month treatment period. 
  Adverse effects were similar in all groups and included 
headache, infection, urinary tract infection, accidental injury, 
pharyngitis, myasthenia, paresthesia, rash, pruritis, back 
pain, diarrhea and sinusitis. One death due to pleural carci-
nomatosis complicated by hemothorax was reported in the 
placebo group. 
Comparative Studies 
 INF-1b has been directly compared to INF-1a 30 mcg 
IM formulation in patients with RRMS in a multi-center, 
randomized, 2-year trial (INCOMIN trial), which enrolled 
188 patients with RRMS [74]. Significantly more patients 
receiving IFN-1b remained relapse-free (51% vs. 36%) and 
remained free from new MRI lesions (55% vs. 26%). It, 
however, was associated with high level of neutralizing anti-
bodies (22% vs. 6%; p < 0.01) [75]. Headache and injection 
site reactions occurred more frequently in the IFN-1b 
treated patients [76]. An open-label Danish study showed no 
differences in relapses, disease progression or adverse effects 
between IFN-1b and IFN-1a SC formulation after one year 
of therapy [77].  
  A small, single-blinded, randomized, 2-year trial sug-
gested that IFN-1b and both IFN-1a formulations provided 
statistically significant efficacy in RRMS patients [78]. Sub-
cutaneous products, but not intramuscular product, were as-
sociated with significant reductions in EDSS. An open label 
study (n = 58) has suggested that IFN-1b was equally effec-
tive and tolerated as glatiramer 20 mg daily or every other 
day [79]. All treatments provided comparable benefits in 
relapses and EDSS scores. IFN-1b was associated with a 
slower progression in disability but glatiramer was better 
tolerated. Another open label study suggested that INF-1b 
and glatiramer, but not INF-1a (Avenex
®) significantly re-
duced relapse rate [80]. 
  A retrospective, open-label study also suggested 
glatiramer reduced relapses more than interferons [81]. An 
open label study showed that delaying therapy with 
glatiramer increases the risk of neurologic disability in pa-
tients with RRMS [81]. When compared to IFN-1b in an 
open label study involving RRMS patients, glatiramer was 
associated with better side effect profile, whereas INF-1b 
slowed the progression of disability more significantly [82]. 
The combination therapy with INF-1b and glatiramer in the 
treatment of MS is being explored [83]. 
DRUGS UNDER DEVELOPMENT 
  Cladribine is a purine nucleoside anti-neoplastic agent 
that is postulated to modulate the T-cell mediated processes 
in MS [84]. To date, cladribine has been studied in one phase 
III trial in patients with chronic progressive MS. In the dou-
ble-blind, randomized, placebo controlled trial, patients 
started with a 4-week screening phase, followed by one year 
of a double-blind phase, and then entered into a 6 year exten-
sion study. In group 1, patients were given cladribine 0.07 
mg/kg/day SC for 5 consecutive days for 6 months, followed 
by 2 months of placebo; in group 2, patients were given cla-
dribine SC 0.07 mg/kg/day for 5 consecutive days for 2 
months, followed by placebo for 6 months; in group 3, pa-
tients were given placebo for 8 months. At the end of the 
treatment phase, the cladribine groups did not differ from the 
placebo group in terms of disability scores, but did show 
fewer gadolinium-enhancing lesions on MRI. At the end of 
the study, the proportion of patients with gadolinium-
enhancing lesions decreased by 70% in the group 1, and by 
83% in group 2, as compared to 18% in the placebo group. 
Treatment-related adverse events included muscle weakness, 
hypertonia, purpura, rhinitis, ataxia, and upper respiratory 
tract infection.  
  Fingolimod is a sphingosine-1-phosphate (S1P) receptor 
agonist which causes down-regulation of the S1P receptor, 
leading to sequestration of T-cells in the thymus and secon-
dary lymphoid organs [85]. Suppressing the migration of T-
cells can help reduce the autoimmune activity in MS. Fingo-
limod has been evaluated in the treatment of RRMS in one 
phase II trial [86]. In the double-blind, placebo-controlled 
study, 281 patients received oral regimens of either fingoli-
mod 1.25mg, 5mg or placebo once daily for 6 months. In the 
extension phase of the study, patients receiving placebo were 
crossed over to receive fingolimod at 1.25 mg or 5 mg daily 
for 6 months. Patients initially receiving fingolimod contin-
ued the drug at the same dose for another 6 months. At the 
end of the first 6 months, the number of gadolinium-
enhanced lesions was lower in the fingolimod 1.25 mg and 5 
mg groups than in the placebo group (8.4, 5.7, and 14.8 le-
sions, respectively; p<0.001). At the end of 12 months, the 
number of gadolinium-enhanced lesions was similar in pa-
tients who received placebo followed by fingolimod as in 
patients who had received fingolimod for the entire 12 
months. Adverse event occurring commonly in the fingoli-
mod patients included nasopharyngitis, dyspepsia, headache, 
somnolence, diarrhea, and nausea. Elevations in alanine 
transaminase were seen in the fingolimod 1.25 mg and 5 mg 
group. A phase III study is currently underway [87]. 
CONCLUSION 
  MS continues to be a complex and devastating disease. 
Many questions still exist regarding its etiology and patho-
physiology, making an appropriate approach to treatment 
challenging. A few disease modifying agents are available. 
While interferon beta 1a and 1b have relatively long-term 
clinical experience in patients with RRMS, the beta 1b for-
mulation recently demonstrated its effect in delaying the 
time to diagnosis of definite MS. Glatiramer and natalizu-
mab have both established efficacy in relapsing forms of 
multiple sclerosis; whereas mitoxantrone is more commonly 
used in patients with advanced disease. Although all disease 
modifying agents reduce MS relapses by interacting with the 
immunologic system, each of them have side effects that 
requires specific clinical monitoring. More data on compara-
tive efficacy and long term information on safety are eagerly 
awaited. The effects of investigational compounds are also 
greatly anticipated, and may provide hopes of addressing the Disease Modifying Agents for Multiple Sclerosis  The Open Neurology Journal, 2010, Volume 4    23 
challenges in reducing or delaying the distressing MS-related 
health concerns. 
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